1: Kim J, Park S, Kim S, Ryu S, Hwang H, Cho S, Han Y, Kim J, Park Y, Lee EK, Lee M. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells. Prostate. 2024 Jun;84(9):814-822. doi: 10.1002/pros.24700. Epub 2024 Apr 1. PMID: 38558458.
2: Chatterjee P, Bhowmik D, Roy SS. A systemic analysis of monocarboxylate transporters in ovarian cancer and possible therapeutic interventions. Channels (Austin). 2023 Dec;17(1):2273008. doi: 10.1080/19336950.2023.2273008. Epub 2023 Nov 7. PMID: 37934721; PMCID: PMC10631444.
3: Padilla J, Lee BS, Zhai K, Rentz B, Bobo T, Dowling NM, Lee J. A Heme-Binding Transcription Factor BACH1 Regulates Lactate Catabolism Suggesting a Combined Therapy for Triple-Negative Breast Cancer. Cells. 2022 Mar 31;11(7):1177. doi: 10.3390/cells11071177. PMID: 35406740; PMCID: PMC8997507.
4: Khan A, Valli E, Lam H, Scott DA, Murray J, Hanssen KM, Eden G, Gamble LD, Pandher R, Flemming CL, Allan S, Osterman AL, Haber M, Norris MD, Fletcher JI, Yu DMT. Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition. Oncogene. 2020 Apr;39(17):3555-3570. doi: 10.1038/s41388-020-1235-2. Epub 2020 Mar 2. PMID: 32123312; PMCID: PMC7970707.
5: Murray CM, Hutchinson R, Bantick JR, Belfield GP, Benjamin AD, Brazma D, Bundick RV, Cook ID, Craggs RI, Edwards S, Evans LR, Harrison R, Holness E, Jackson AP, Jackson CG, Kingston LP, Perry MW, Ross AR, Rugman PA, Sidhu SS, Sullivan M, Taylor-Fishwick DA, Walker PC, Whitehead YM, Wilkinson DJ, Wright A, Donald DK. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol. 2005 Dec;1(7):371-6. PubMed PMID: 16370372.